DaVita (BSP:DVAI34) Short Interest


BSP:DVAI34 DaVita Inc BSP:DVAI34
75 GF Score
Price R$1,151.37
GF Value R$900.89
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is DaVita Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BSP:DVAI34 vs THC, EHC, ENSG: Short Interest Comparison

For the Medical Care Facilities subindustry, DaVita's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DaVita Short Interest vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DaVita's Short Interest distribution charts can be found below:

* The bar in red indicates where DaVita's Short Interest falls into.


BSP:DVAI34
75GF Score
DaVita Inc BSP:DVAI34
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is DaVita (BSP:DVAI34) Overvalued in 2026?

Based on GuruFocus' analysis, DaVita stock appears to be overvalued. The current stock price of R$1,151.37 is trading 27.8% above its estimated GF Value™ of R$900.89. GuruFocus considers DaVita to be Modestly Overvalued.

Key valuation signals for BSP:DVAI34:

  • Short Interest:
  • GF Value™: R$900.89 vs. price of R$1,151.37 (27.8% above fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the BSP:DVAI34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DaVita Business Description

Address 2000 16th Street, Denver, CO, USA, 80202
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
75GF Score

Get the complete analysis for BSP:DVAI34

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$1,151.37
Price
R$900.89
GF Value